PerkinElmer, Inc. (NYSE:PKI) Stock Holdings Lifted by Tyers Asset Management LLC

Tyers Asset Management LLC lifted its stake in shares of PerkinElmer, Inc. (NYSE:PKI) by 3.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,280 shares of the medical research company’s stock after acquiring an additional 198 shares during the quarter. Tyers Asset Management LLC’s holdings in PerkinElmer were worth $509,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Amica Retiree Medical Trust acquired a new position in PerkinElmer in the 2nd quarter valued at approximately $48,000. Coastal Capital Group Inc. acquired a new stake in PerkinElmer during the 2nd quarter worth $58,000. Signaturefd LLC raised its stake in PerkinElmer by 171.5% during the 1st quarter. Signaturefd LLC now owns 809 shares of the medical research company’s stock worth $78,000 after buying an additional 511 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in shares of PerkinElmer in the 2nd quarter valued at about $78,000. Finally, Hilton Capital Management LLC bought a new position in shares of PerkinElmer in the 1st quarter valued at about $82,000. 95.19% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:PKI traded up $0.90 during trading on Friday, hitting $87.02. 9,647 shares of the stock traded hands, compared to its average volume of 602,311. The company has a quick ratio of 1.31, a current ratio of 1.89 and a debt-to-equity ratio of 0.84. The company has a market cap of $9.50 billion, a price-to-earnings ratio of 24.11, a P/E/G ratio of 1.52 and a beta of 1.29. The company has a fifty day moving average price of $84.28 and a two-hundred day moving average price of $91.45. PerkinElmer, Inc. has a 52-week low of $71.83 and a 52-week high of $103.00.

PerkinElmer (NYSE:PKI) last announced its earnings results on Monday, July 29th. The medical research company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.01). The business had revenue of $722.50 million for the quarter, compared to analyst estimates of $729.10 million. PerkinElmer had a return on equity of 16.07% and a net margin of 9.01%. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period last year, the firm earned $0.91 EPS. On average, equities research analysts predict that PerkinElmer, Inc. will post 4.04 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 8th. Stockholders of record on Friday, October 18th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date is Thursday, October 17th. PerkinElmer’s dividend payout ratio is presently 7.76%.

Several research analysts have commented on the stock. Wood & Company restated an “average” rating and set a $49.00 price objective on shares of PerkinElmer in a research report on Friday, July 19th. ValuEngine lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a report on Wednesday, July 31st. Raymond James began coverage on shares of PerkinElmer in a research note on Wednesday, July 10th. They issued an “outperform” rating for the company. UBS Group increased their target price on shares of PerkinElmer from $99.00 to $101.00 and gave the company a “neutral” rating in a research report on Tuesday, July 30th. Finally, Zacks Investment Research upgraded shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $89.00 target price on the stock in a research note on Thursday, May 30th. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. PerkinElmer has a consensus rating of “Hold” and a consensus target price of $76.23.

In other news, Director Alexis P. Michas sold 2,000 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $82.56, for a total value of $165,120.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.80% of the company’s stock.

PerkinElmer Company Profile

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Read More: Do closed-end mutual funds pay dividends?

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.